Björn Kruspig Person-Info 

( Ich bin Björn Kruspig)

News

Afatinib push back K-RAS-positive lung cancer - European Biotechnology

european-biotechnology.com
A team of Austrian, Hungarian and Canadian researchers has demonstrated that Boehringer Ingelheim's FDA-approved ERB family kinase blocker afatinib prolonged...

Established medications combat lung cancer tu | EurekAlert!

www.eurekalert.org
Two research groups have discovered that the growth of an intractable type of lung cancer in mouse models can be restrained with a class of drug known as...

Existing treatment could be used for common 'untreatable' form of...

medicalxpress.com
More information: Björn Kruspig et al. The ERBB network facilitates KRAS-driven lung tumorigenesis, Science Translational Medicine (2018).
Dossier exportieren
+1